Online citations, reference lists, and bibliographies.
← Back to Search

Epithelial Malignant Pleural Mesothelioma After Extrapleural Pneumonectomy: Stratification Of Survival With CT-derived Tumor Volume.

R. Gill, W. Richards, B. Yeap, Shin Matsuoka, A. Wolf, V. Gerbaudo, R. Bueno, D. Sugarbaker, H. Hatabu
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE The purpose of this study was to assess the usefulness of CT-derived tumor volume, with control for other prognostic factors, for stratifying survival after surgery-based multimodality treatment of a large cohort of patients with epithelial malignant pleural mesothelioma. MATERIALS AND METHODS We retrospectively reviewed 338 patients with mesothelioma who underwent extrapleural pneumonectomy between 2001 and 2007. The study cohort comprised 88 patients with epithelial subtype tumors, DICOM-format CT scans, and data regarding neoadjuvant and adjuvant therapy. Tumor volume was calculated, and Kaplan-Meier survival and Cox regression analyses were performed to compare the estimated survival functions of patient subgroups based on volume and other covariates related to outcome (sex, age, preoperative platelet count, hemoglobin concentration, WBC count, clinical and pathologic TNM category, and administration of neoadjuvant and adjuvant therapy). A multivariate regression model was derived on the basis of the most significant univariate predictors. RESULTS The median estimated tumor volume was 319 cm(3) (range, 4-3256 cm(3)). In univariate analysis, tumor volume, hemoglobin concentration, platelet count, pathologic TNM category, and administration of adjuvant chemotherapy or radiation therapy met the criteria for inclusion in the reverse stepwise regression analysis. In the final model, tumor volume, hemoglobin concentration, and administration of adjuvant chemotherapy or radiotherapy were identified as independently associated with overall survival. CONCLUSION With control of prognostic covariates, CT-derived tumor volume can be used to stratify survival of patients with epithelial mesothelioma after extrapleural pneumonectomy and should be included in prognostic evaluation of patients for whom resection is being considered.
This paper references
10.1002/cncr.24886
Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases
W. Richards (2010)
10.1109/IEMBS.2005.1616473
HIPPA's compliant Auditing System for Medical Imaging System
Xiaomeng Chen (2005)
10.1111/j.1759-7714.2012.00127.x
Clinical and biologic prognostic factors in malignant pleural mesothelioma
V. Ambrogi (2012)
10.1016/j.jtcvs.2012.12.037
Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.
D. Sugarbaker (2013)
10.1055/s-0029-1241029
Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.
J. Pilling (2010)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1016/j.lungcan.2013.08.005
Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group.
S. Armato (2013)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1097/00005382-200605000-00006
Preoperative Evaluation of Patients With Malignant Pleural Mesothelioma: Role of Integrated CT-PET Imaging
M. Truong (2006)
10.1016/S0022-5223(03)00207-1
Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
R. Flores (2003)
10.1158/1078-0432.CCR-09-2313
A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters
A. Nowak (2010)
10.1093/jnci/djp061
Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma.
G. Gordon (2009)
10.1136/thorax.55.9.731
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1016/J.RO.2004.04.005
Imaging evaluation in the diagnosis and staging of malignant pleural mesothelioma.
M. Truong (2004)
10.1016/j.ejcts.2009.12.039
Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage?
A. Nakas (2010)
10.1053/j.semtcvs.2013.07.002
The state of the art in the technical performance of lung-sparing operations for malignant pleural mesothelioma.
J. Friedberg (2013)
10.1245/s10434-010-1107-z
Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications
H. Lee (2010)
10.1002/JSO.1143
Survival after conservative (palliative) management of pleural malignant mesothelioma
N. Merritt (2001)
10.1016/j.ejcts.2008.07.050
Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy.
J. Sørensen (2008)
10.1016/J.LUNGCAN.2005.03.015
Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience.
R. Flores (2005)
10.2214/AJR.172.4.10587144
Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.
R. Heelan (1999)
10.1007/s00330-008-0918-9
Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT
C. Plathow (2008)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1016/S1470-2045(13)70139-6
Mesothelioma: closer to the target?
H. Pass (2013)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1053/j.ro.2013.03.017
Malignant pleural mesothelioma: role of CT, MRI, and PET/CT in staging evaluation and treatment considerations.
M. Truong (2013)
10.1016/S0022-5223(98)70274-0
Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.
H. Pass (1998)
10.3816/CLC.2009.n.033
Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.
Brad E Wilcox (2009)
10.1097/JTO.0b013e3181dd0ef1
Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed Tomography Scans
F. Liu (2010)



This paper is referenced by
10.1259/bjr.20180631
Volumetric analysis at abdominal CT: oncologic and non-oncologic applications.
Virginia B. Planz (2019)
10.1016/S1470-2045(13)70139-6
Mesothelioma: closer to the target?
H. Pass (2013)
10.21037/atm.2017.05.23
Volumetric assessment in malignant pleural mesothelioma.
D. Murphy (2017)
10.1016/j.lungcan.2020.09.025
A comparison between MRI and CT in the assessment of primary tumour volume in mesothelioma.
S. Tsim (2020)
10.1053/j.semtcvs.2015.05.003
Induction Therapy for Mesothelioma.
I. Opitz (2015)
10.1093/jnci/djx175
Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma
R. Gill (2018)
10.1097/JTO.0000000000000181
Supplementary Prognostic Variables for Pleural Mesothelioma
H. Pass (2014)
10.1111/j.1759-7714.2012.00127.x
Clinical and biologic prognostic factors in malignant pleural mesothelioma
V. Ambrogi (2012)
10.1093/annonc/mdy195
Pleural mesothelioma: is the surgeon still there?
I. Opitz (2018)
Malignant pleural mesothelioma: factors influencing the prognosis.
T. Mineo (2012)
10.1053/j.ro.2013.03.017
Malignant pleural mesothelioma: role of CT, MRI, and PET/CT in staging evaluation and treatment considerations.
M. Truong (2013)
10.5301/tj.5000418
Clinical and Pathologic Predictors of Clinical Outcome of Malignant Pleural Mesothelioma
R. Berardi (2016)
10.1183/09031936.00207213
Multimodal management of malignant pleural mesothelioma: where are we today?
P. V. Van Schil (2014)
10.1097/JTO.0000000000000661
A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years’ Experience
I. Opitz (2015)
10.1016/j.lungcan.2013.08.005
Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group.
S. Armato (2013)
10.21037/jtd.2017.03.27
Malignant pleural mesothelioma: key determinants in tailoring the right treatment for the right patient.
Ori Wald (2017)
10.1093/ejcts/ezv422
Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
Diana Y. Kircheva (2016)
10.1016/S1470-2045(17)30459-X
Radiotherapy for the treatment of malignant pleural mesothelioma.
M. Perrot (2017)
10.1016/j.jtho.2016.04.027
North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study
R. Gill (2016)
10.1007/978-3-319-96244-3
Caring for Patients with Mesothelioma: Principles and Guidelines
M. Hesdorffer (2019)
10.1016/j.lungcan.2018.11.033
Imaging in pleural mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
S. Armato (2019)
10.1016/j.athoracsur.2017.06.042
Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
B. Burt (2017)
10.1017/9781316402009.004
Multi-modality Imaging of Pleural and Peritoneal Disease
J. Cunningham (2018)
10.1016/j.jtho.2016.09.121
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
D. Rice (2016)
10.5772/intechopen.91769
Predictive and Prognosis Factors of Clinical Utility in Mesothelioma
Rodríguez-Cid Jeronimo Rafael (2020)
10.18632/oncotarget.15404
Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis.
N. Chen (2017)
10.1016/j.ijsu.2017.10.034
The revised staging system for malignant pleural mesothelioma based on surveillance, epidemiology, and end results database.
S. Wang (2017)
10.1053/j.semtcvs.2013.07.002
The state of the art in the technical performance of lung-sparing operations for malignant pleural mesothelioma.
J. Friedberg (2013)
Clinicopathologic indices can improve patient selection in malignant mesothelioma.
D. Sugarbaker (2012)
10.1016/j.jtcvs.2012.12.037
Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.
D. Sugarbaker (2013)
10.1055/s-0039-1693406
Malignant Mesothelioma: Has Anything Changed?
Roger Y Kim (2019)
10.3978/j.issn.2225-319X.2012.11.12
Multimodality therapy for malignant pleural mesothelioma.
W. Weder (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar